Crispr's stock is down 5% after sharing early-stage data for its CAR-T therapy candidateMarket Watch • 10/13/21
CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignanciesGlobeNewsWire • 10/12/21
CRISPR Therapeutics AG (CRSP) CEO Samarth Kulkarni Presents at Chardan's 5th Annual Genetic Medicines Conference Call TranscriptSeeking Alpha • 10/04/21
Here's Why Editas Stock Dropped After Data From CRISPR-Based Retinal Disorder CandidateBenzinga • 09/29/21
CRISPR Therapeutics to Participate in the Chardan's 5th Annual Genetic Medicines ConferenceGlobeNewsWire • 09/28/21
Why CRISPR Therapeutics AG (CRSP) is a Top Stock for the Long-TermZacks Investment Research • 09/17/21
CRISPR Therapeutics AG (CRSP) Stock Moves -0.59%: What You Should KnowZacks Investment Research • 09/11/21